MEISSNER, W. G.; FERNAGUT, P. O.; DEHAY, B.; PERAN, P.; TRAON, A. P.; FOUBERT-SAMIER, Alexandra; LOPEZ CUINA, M.; BEZARD, E.; TISON, F.; RASCOL, O.

doi:10.1002/mds.27894

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Movement disorders. 2019-11, vol. 34, n° 11, p. 1629-1642

Résumé en anglais

Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions, which qualifies MSA as a synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. The underlying pathogenesis is still not well understood. Some symptomatic treatments are available, whereas neuroprotection remains an urgent unmet treatment need. In this review, we critically appraise significant developments of the past decade with emphasis on pathogenesis, diagnosis, prognosis, and treatment development. We further discuss unsolved questions and highlight some perspectives. (c) 2019 International Parkinson and Movement Disorder Society.< Réduire

Mots clés en anglais

SEPIA

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Multiple System Atrophy: Recent Developments and Future Perspectives

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche